Skip to main content
Carisma Therapeutics Inc. logo

Carisma Therapeutics Inc. — Investor Relations & Filings

Ticker · CARM ISIN · US14216R1014 LEI · 549300DGKHONOZQIY116 US Manufacturing
Open in API
Filings indexed 853 across all filing types
Latest filing 2025-10-01 Regulatory Filings
Country US United States of America
Listing US CARM

About Carisma Therapeutics Inc.

https://sesenbio.com/

Carisma Therapeutics Inc. is a clinical-stage biotechnology company pioneering the development of engineered macrophage-based therapeutics. The company's proprietary cell therapy platform is centered on Chimeric Antigen Receptor Macrophages (CAR-M) and CAR-Monocytes. This approach is designed to leverage the unique abilities of macrophages to infiltrate solid tumors, overcome the immunosuppressive tumor microenvironment, and stimulate a broad anti-tumor response. Carisma's pipeline is focused on developing treatments for cancer and other serious disorders, including fibrosis.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-10-01 English
RW
Regulatory Filings Classification · 100% confidence The document is a letter from Carisma Therapeutics Inc. to the SEC requesting withdrawal of a previously filed Registration Statement on Form S-4 related to a merger transaction. It references the termination of the merger agreement and states that the company will not proceed with the issuance of securities under that registration statement. The document is a formal withdrawal request and does not contain financial data, audit information, or detailed report content. It is an official regulatory filing related to the withdrawal of a registration statement, which fits best under the category of Regulatory Filings (RNS). The document length is short (3264 characters), and it is clearly a regulatory communication rather than a full report or announcement of a report publication.
2025-09-18 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 16, 2025. It reports on material definitive agreements including an amendment to a collaboration and license agreement and the termination of a merger agreement. The content focuses on corporate events and contractual updates rather than financial results or detailed financial statements. It does not contain quarterly or annual financial data, earnings highlights, or management discussion of financial results. The document is a regulatory filing reporting significant corporate events and contractual changes, typical of an 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-09-18 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-09-02 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-29 English
S-4/A
Merger & Acquisition Classification · 100% confidence The document is an SEC filing titled "Amendment No. 1 to Form S-4 Registration Statement" filed by Carisma Therapeutics Inc. The Form S-4 is a registration statement used for securities issued in connection with mergers and acquisitions. The text discusses a proposed merger, merger agreement details, stockholder meeting for approval, issuance of shares, and concurrent financing related to the merger. It includes detailed merger terms, stock exchange ratios, and financing arrangements. This is clearly a merger-related filing, specifically a registration statement for securities issued in connection with a merger transaction. Therefore, the document fits the category of Merger & Acquisition filings (MA). The document length and content confirm it is not a proxy statement or a simple announcement but a detailed merger registration statement.
2025-08-29 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.